---
schema_version: "secwatch.filing_event.v1"
accession: "0001077183-22-000047"
form_type: "8-K"
ticker: "NEO"
cik: "0001077183"
company_name: "NEOGENOMICS INC"
filed_at: "2022-03-09T23:59:59+00:00"
generated_at: "2026-06-27T00:17:45.348937+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# NeoGenomics announces retirement of COO Cardoza; appoints Sholehvar as President of Clinical Services

## Summary
- George Cardoza, President and COO Lab Ops, to retire effective March 31, 2022.
- Dr. Steven Brodie appointed interim President of Lab Operations.
- Dr. David Sholehvar appointed President, Clinical Services, effective March 14, 2022.
- Sholehvar compensation: $435K base, 50% bonus, $750K equity grant.

## SEC filing metadata
- accession: 0001077183-22-000047
- form_type: 8-K
- ticker: NEO
- cik: 0001077183
- company_name: NEOGENOMICS INC
- filed_at: 2022-03-09T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1077183/000107718322000047/0001077183-22-000047-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1077183/000107718322000047/neo-20220309.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001077183-22-000047
- JSON: https://secwatch.observer/filing/0001077183-22-000047.json
- Plain text: https://secwatch.observer/filing/0001077183-22-000047.txt

## Key facts
- Executive change
  David Sholehvar was appointed as President, Clinical Services Division at NEOGENOMICS INC.
  - Action: appointed
  - Role: President, Clinical Services Division
  source text: Dr. David Sholehvar, age 54, was appointed President, Clinical Services Division of the Company, effective March 14, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1077183/000107718322000047/0001077183-22-000047-index.htm
- Executive change
  George A. Cardoza departed as President and Chief Operating Officer, Laboratory Operations at NEOGENOMICS INC.
  - Action: retire
  - Role: President and Chief Operating Officer, Laboratory Operations
  source text: George A. Cardoza, NeoGenomics, Inc.’s (the “Company”) current President and Chief Operating Officer, Laboratory Operations, informed the Company of his intention to retire from his role effective March 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1077183/000107718322000047/0001077183-22-000047-index.htm
- Executive change
  Steven Brodie was appointed as interim President of Lab Operations at NEOGENOMICS INC.
  - Action: appointed
  - Role: interim President of Lab Operations
  source text: Dr. Steven Brodie, the Company’s current Senior Vice President, Laboratory Operations, has been appointed the Company’s interim President of Lab Operations.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1077183/000107718322000047/0001077183-22-000047-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.